



## Dolutegravir-containing products – New warning

- On September 6, 2018, the [FDA announced](#) an update to the *Warnings and Precautions* section of dolutegravir-containing products drug labels regarding embryo-fetal toxicity.
  - Previously, the [FDA announced](#) a safety communication about neural tube birth defects in May of 2018.
- Dolutegravir-containing products include [Tivicay<sup>®</sup> \(dolutegravir\)](#), [Juluca<sup>®</sup> \(dolutegravir/rilpivirine\)](#) and [Triumeq<sup>®</sup> \(abacavir/dolutegravir/lamivudine\)](#).
  - Tivicay, Juluca, and Triumeq are approved to treat human immunodeficiency virus type 1 infections.
  - Refer to individual drug labels for specific indications.
- Preliminary data from an observational study showed that dolutegravir, was associated with increased risk of neural tube defects when administered at the time of conception and in early pregnancy. As there is limited understanding of reported types of neural tube defects associated with dolutegravir use and because the date of conception may not be determined with precision, avoid use of dolutegravir-containing products at the time of conception through the first trimester of pregnancy.
  - If there are plans to become pregnant or if pregnancy is confirmed within the first trimester while on dolutegravir-containing products, if possible, switch to an alternative regimen.
  - Perform pregnancy testing before initiation of dolutegravir-containing products in adolescents and adults of childbearing potential to exclude use of dolutegravir-containing products during the first trimester of pregnancy.
  - Advise adolescents and adults of childbearing potential to consistently use effective contraception.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.